Olanzapine does not enhance cognition in non-agitated and non-psychotic patients with mild to moderate Alzheimer's dementia.

摘要: Objective This was an exploratory study of olanzapine as potential treatment for improvement in cognition patients with Alzheimer's disease without prominent psychobehavioral symptoms. Methods Non-psychotic/non-agitated (n = 268) disease, who had baseline Mini-Mental State Examination (MMSE) scores 14–26 were randomized to (2.5 7.5 mg/d) or placebo 26 weeks. The primary objectives determine if improved indexed by the Assessment Scale Cognition (ADAS-Cog) and Clinician's Interview-Based Impression Change (CIBIC) after weeks therapy. Results Patients treated vs experienced significant worsening ADAS-Cog at 12 (p = 0.03) (p = 0.004). Changes CIBIC not significantly different between groups either assessment. A post hoc analysis revealed that olanzapine-treated more cognitive impairment (MMSE 14–18) (n = 35) greater deterioration performance than group (n = 24; p < 0.001); whereas less (n = 78, MMSE 23–26) between-group changes significant. Conclusions In this 26-week non-psychotic/non-agitated compared placebo. Copyright © 2005 John Wiley & Sons, Ltd.